Cansino Biotech (06185): TD5CP has been approved in China to conduct clinical trials in people aged 4 to 5

Zhitongcaijing · 3d ago

According to the Zhitong Finance App, Cansino Biotech (06185) issued an announcement. The adsorbed acell-free 100 (five-component) albinism combination vaccine (TD5cP) developed by the company has been approved by the China National Drug Administration, and relevant clinical trials can be carried out in people aged 4 to 5.

Based on the fact that the incidence and severity of adverse reactions of the full-dose co-purified dTAP vaccine will increase as the number of doses of vaccination increases and the vaccination age increases, foreign countries basically used reduced doses of the DTAP vaccine to purify the dTAP vaccine, then booster vaccination began at age 4. Due to the decrease in the antigen content of pertussis and diphtheria, the incidence of adverse reactions of the Tdap vaccine is low.

To apply for this clinical trial, it is proposed to expand the age of enhanced immunity for TD5CP to 4 to 6 years old to stimulate immune memory and rapidly return antibody levels to the scope of effective protection. It not only helps fill the immunization gap before enrollment, but also significantly reduces the risk of outbreaks in childcare institutions and elementary schools, and provides key support for establishing an immune barrier and controlling the spread of pertussis throughout the age.